Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.57 |
| ▸ | JAK1 | P23458 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23581368 | 0.84 | NR1H2 (0.57) | NR1H2JAK1JAK2GPR119DPP4 | |
| SCHEMBL19074507 | 0.83 | GPR119 (0.48) | NR1H2JAK1JAK2GPR119DPP4 | |
| SCHEMBL22655482 | 0.83 | GPR119 (0.48) | NR1H2JAK1JAK2GPR119DPP4 | |
| SCHEMBL122218 | 0.83 | GPR119 (0.50) | GPR119DPP4USP2SMN1; SMN2EPHX1 | |
| SCHEMBL26791050 | 0.82 | NR1H2 (0.62) | NR1H2JAK1JAK2GPR119DPP4 | |
| SCHEMBL15907025 | 0.82 | NR1H2 (0.62) | NR1H2JAK1JAK2GPR119DPP4 | |
| SCHEMBL28981659 | 0.81 | MEN1 (0.35) | NR1H2USP2 | |
| SCHEMBL23581350 | 0.80 | NR1H2 (0.59) | NR1H2JAK1JAK2GPR119DPP4 | |
| SCHEMBL1662404 | 0.80 | NR1H2 (0.51) | NR1H2GPR119DPP4USP2SMN1; SMN2 | |
| SCHEMBL24714052 | 0.79 | NR1H2 (0.62) | NR1H2JAK1JAK2GPR119DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114787143-A | ZESTE enhancer homolog 2 inhibitors and uses thereof | 四川海思科制药有限公司 | 2022-07-22 | — | — | CN | disclosed |
| WO-2021129629-A1 | ZESTE ENHANCER HOMOLOGUE 2 INHIBITOR AND USE THEREOF | 四川海思科制药有限公司 | 2021-07-01 | — | — | WO | disclosed |
| US-20170015658-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2017-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015658-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | HAVCR2, MAVS, FABP1 | NR1H2 148/4885JAK1 2373/4885JAK2 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.